UCL Institute of Child Health London UK

UCL Institute of Child Health London UK

Contact information:

Institute & address

UCL Institute of Child Health,

30 Guilford Street 

London WC1N 1EH

Tel : 44 (0) 207 905 2391 

Fax : 44 (0) 207 905 2882 

Email: l.wedderburn@ucl.ac.uk


Who is who?


PI’s and Key staff members and expertise: 

PI Lucy Wedderburn, Professor of Paediatric Rheumatology

Director, Arthritis Research UK Centre for Adolescent Rheumatology at UCL , UCLH and GOSH 

Deputy Head, Infection, Immunity and Inflammation Programme, UCL Institute of Child Health – Unit website  


Section teams Clinical and Lab: 

Prof Paul Brogan, Professor of Vasculitis, Head of Infection, Inflammation and Rheumatology Section and Consultant Paediatric Rheumatology

Dr Despina Eleftheriou Clinical Fellow and Consultant Paediatric Rheumatology



Dr Clarissa Pilkington, Consultant Paediatric Rheumatology

Dr Sandrine Lacassagne Consultant Paediatric Rheumatology

Dr Muthana Al Obadi Consultant Paediatric Rheumatology

Dr Debajit Sen, Adolescent Rheumatology Consultant

Ms Sue Maillard Clinical Specialist Physiotherapist in Paediatric Rheumatology 



Wedderburn group:


Dr Clare Deakin, Research Associate

Ms Chantal Duurland, EUTRAIN PhD Fellow/Research Assistant

Ms Lucy Marshall, Research Assistant

Ms Hannah Lom, PhD Student, Arthritis Research UK Centre for Adolescent Rheumatology

Dr Jason Palman, Clinical Research Associate

Dr Lizzy Rosser, Arthritis Research UK post doctoral Foundation Fellow

Dr Sherry Yasin, Research Associate


Support Staff

Ms Brenda Bell, Administrator, Centre for Adolescent Rheumatology

Ms Hema Chaplin, Research Facilitator

Ms Yvonne Glackin, POPS/SLE Study Coordinator

Ms Clare Heard, CHART Study Coordinator

Ms Natasha Makengo, CAPS Data Manager 

Ms Emily Robinson, JIA Study Coordinator

Ms Stephanie Simou, JDRG Study Coordinator


Short summary research: 

The key focus of the Wedderburn laboratory is the immunopathogenesis of childhood arthritis and myositis, with emphasis on immune regulation, in particular T cell responses and regulatory T cells and the dynamic immunomodulation driven by inflammation.  My group has a major programme of work focusing on the mechanisms of severity of disease and predictors of response to medication. We lead a large study of response to drug treatment in JIA known as Childhood Arthritis Response to Medication Study or CHARMS with National and International partners and a UK wide Consortium CHART that is bringing together 4 key large cohort studies in JIA from across the UK

 L Wedderburn leads the UK wide cohort study in juvenile dermatomyositis (JDM), a resource which acts as a platform for basic translational and clinical research into JDM see http://www.juveniledermatomyositis.org.uk and is the Director of the Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH and GOSH , http://www.centre-for-adolescent-rheumatology.org



Our translational research programme is aimed at the design of biomarkers and predictors of outcome and response to treatment with the ultimate goal of designing diagnostic and therapeutic predictive tools to facilitate personalized medicine and ultimately improve the lives of children with autoimmune rheumatic diseases.  

Our group is fully integrated into the National effort of research in Paediatric Rheumatology through contributions to the Clinical Studies group in Paediatric Rheumatology http://www.arthritisresearchuk.org/arthritis_research/clinical_study_groups/csg_-_mcrn_paediatric_rheumato.aspx

the British Society for Paediatric and Adolescent Rheumatology


Funding sources:

Sparks UK 

Arthritis Research UK

Wellcome Trust

Action Medical   

Myositis Support Group UK

Medical Research Council

National Institute for Health Research


Relevant links:




Sparks UK

Arthritis Research UK  

Wellcome Trust

Action Medical   

Myositis Support Group UK

Standardised operating procedure (SOP) for collection and processing of bio–‐ specimens in studies of juvenile idiopathic arthritis (JIA) in association with the Childhood Arthritis response to Treatment Consortium, CHART:

CHART_SOP_PACKAGE final 020316